RETATRUTIDE | RETA-X
XENE BIOLABS RESEARCH SERIES
FOR RESEARCH USE ONLY
Category: GLP-1/GIP/Glucagon Tri-Agonist | Half-life: 6 days
Mechanism
Triple incretin agonist. GLP-1 + GIP + glucagon receptor activation. Superior weight loss to Semaglutide/Tirzepatide. Phase 3 trials.
Dosing Protocol
Critical: Slow titration mandatory. Severe nausea/vomiting if escalated too fast. Not FDA-approved yet. Research only.
RETA-6X / RETA-12X | GLP-1 / GIP / Glucagon Triple Agonist | CAS: 2381089-83-2
Retatrutide is a next-generation triple incretin receptor agonist that simultaneously targets GLP-1, GIP, and glucagon receptors. It is designed to support significant fat loss through appetite suppression, increased energy expenditure, and improved insulin sensitivity. Clinical studies have demonstrated body weight reductions of up to 24%, making it one of the most promising compounds in metabolic health and weight management.
Dosing Protocol
| Parameter | Details |
|---|---|
| Starting Dose | 2 mg subcutaneous injection once weekly |
| Titration | Increase by 2 mg every 4 weeks as tolerated |
| Maintenance Dose | 6–12 mg per week (6X = 6 mg vial, 12X = 12 mg vial) |
| Administration Route | Subcutaneous injection in the abdomen, thigh, or upper arm |
| Cycle Length | 12–24 weeks, with reassessment after 12 weeks |
| Reconstitution | Mix with 1–2 mL bacteriostatic water per vial |
Stacking Recommendations
For enhanced growth hormone support, Retatrutide may be combined with Tesamorelin or a CJC-1295 and Ipamorelin protocol. For additional metabolic support, 5-Amino-1MQ may be considered. Concurrent use with other GLP-1 receptor agonists is generally not recommended. Supporting supplements such as Omega-3 fatty acids and Berberine may help maintain cardiovascular and metabolic health.
Note: Nausea is the most commonly reported side effect. Gradual dose escalation is recommended to improve tolerability. Regular monitoring of fasting glucose and lipase levels is advised. Avoid use in individuals with a history of pancreatitis.
From Collection
BPC158+TB500
XENE BIOLABS RESEARCH SERIES
FOR RESEARCH USE ONLY
Category: Healing Peptides | Half-life: BPC ~4h, TB-500 7-14 days
Mechanism
BPC-157 = gastric peptide, upregulates growth factors, angiogenesis, gut healing. TB-500 = Thymosin Beta-4 fragment, actin regulation, cell migration.
Dosing Protocol
Reconstitution: 5 mg each + 2.5 mL BAC = 2 mg/mL. 250 mcg = 0.125 mL = 12.5 units.
Critical: BPC site injection for local effect. TB-500 systemic. Can mix in same syringe.